公开(公告)号：US20210196833A1

公开(公告)日：2021-07-01

申请号：US17204183

申请日：2021-03-17

申请人： FIDIA FARMACEUTICI S.P.A.

发明人： Giorgio MOSCONI ,  Daniela JABES ,  Carlo PIZZOCARO

IPC分类号： A61K47/61 ,  A61K31/337

摘要： A pharmaceutical composition is described, essentially consisting of the paclitaxel prodrug associated with pharmacologically acceptable diluents/excipients, for use in the treatment of non-muscle invasive bladder cancer (NMIBC) by means of intravesical instillations according to a single weekly dose of 600 mg of said prodrug, or two weekly doses equal to a total of 1,200 mg, for 12 or 6 consecutive weeks of treatment.
The paclitaxel prodrug used was prepared according to an indirect synthesis process between molecules of hyaluronic acid (HA) and paclitaxel by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and chemotherapeutic agent.

公开(公告)号：US20240123077A1

公开(公告)日：2024-04-18

申请号：US18539827

申请日：2023-12-14

申请人： FIDIA FARMACEUTICI S.P.A.

发明人： Giorgio MOSCONI ,  Daniela JABES ,  Carlo PIZZOCARO

IPC分类号： A61K47/61 ,  A61K31/337

CPC分类号： A61K47/61 ,  A61K31/337

摘要： A pharmaceutical composition includes a paclitaxel prodrug associated with pharmacologically acceptable diluents/excipients for use in the treatment of non-muscle invasive bladder cancer (NMIBC) by intravesical instillations according to a single weekly dose of 600 mg of the prodrug, or two weekly doses equal to a total of 1,200 mg, for 12 or 6 consecutive weeks of treatment. The paclitaxel prodrug used was prepared according to an indirect synthesis process between molecules of hyaluronic acid (HA) and paclitaxel by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and chemotherapeutic agent.

公开(公告)号：US20210268119A1

公开(公告)日：2021-09-02

申请号：US17315962

申请日：2021-05-10

申请人： FIDIA FARMACEUTICI S.P.A.

发明人： Giorgio MOSCONI ,  Daniela JABES ,  Carlo PIZZOCARO

IPC分类号： A61K47/61 ,  A61K31/337

摘要： A pharmaceutical composition is described, essentially consisting of the paclitaxel prodrug associated with pharmacologically acceptable diluents/excipients, for use in the treatment of non-muscle invasive bladder cancer (NMIBC) by means of intravesical instillations according to a single weekly dose of 600 mg of said prodrug, or two weekly doses equal to a total of 1,200 mg, for 12 or 6 consecutive weeks of treatment. The paclitaxel prodrug used was prepared according to an indirect synthesis process between molecules of hyaluronic acid (HA) and paclitaxel by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and chemotherapeutic agent.